Who are TETA 4HCL (60-<W108)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cordarone, amiodarone amiodarone, Sevoflurane Inhalational Induction and Maintenance, Desflurane Inhalant Product, Minoxidil Topical, metformin+ gliclazide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/teta-4hcl-60-w108.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

TETA 4HCL (60-<W108) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TETA 4HCL (60-<W108) (TETA 4HCL (60-<W108)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium channel blocker. Area: Cardiovascular.

phase 3 Potassium channel blocker Potassium channels Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

TETA 4HCL (60-<W108) (TETA 4HCL (60-<W108)) — Orphalan. TETA 4HCL is a tetraethylammonium chloride, a potassium channel blocker.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TETA 4HCL (60-<W108) TARGET	TETA 4HCL (60-<W108)	Orphalan	phase 3	Potassium channel blocker	Potassium channels
Cordarone	AMIODARONE	Pfizer	marketed	Antiarrhythmic	sodium channels, potassium channels, calcium channels	1985-01-01
amiodarone amiodarone	amiodarone amiodarone	National Heart, Lung, and Blood Institute (NHLBI)	marketed	Class III antiarrhythmic agent	Potassium channels (hERG), sodium channels, beta-adrenergic receptors, calcium channels
Sevoflurane Inhalational Induction and Maintenance	Sevoflurane Inhalational Induction and Maintenance	Abbott	marketed	Volatile anesthetic agent	GABA receptors, NMDA receptors, potassium channels
Desflurane Inhalant Product	Desflurane Inhalant Product	Sichuan Provincial People's Hospital	marketed	Volatile inhalational anesthetic	GABA receptors, NMDA receptors, potassium channels
Minoxidil Topical	Minoxidil Topical	Dr. dr. Lili Legiawati, SpKK(K)	marketed	Potassium channel opener	ATP-sensitive potassium channels
metformin+ gliclazide	metformin+ gliclazide	GlaxoSmithKline	marketed	Antidiabetic combination (biguanide + sulfonylurea)	Metformin: mitochondrial glycerophosphate dehydrogenase; Gliclazide: ATP-sensitive potassium channels on pancreatic beta cells

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Potassium channel blocker class)

Orphalan · 3 drugs in this class
Biogen · 2 drugs in this class
Essentialis, Inc. · 1 drug in this class
National Center for Research Resources (NCRR) · 1 drug in this class
Oregon Health and Science University · 1 drug in this class
Sheba Medical Center · 1 drug in this class
University of Southern Denmark · 1 drug in this class
D'Youville College · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TETA 4HCL (60-<W108) — Competitive Intelligence Brief. https://druglandscape.com/ci/teta-4hcl-60-w108. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab